Technologies Empowering Diagnostics - Genetic TOE

USD 1,500.00

* Required Fields

USD 1,500.00

PAY BY INVOICE

Be the first to review this product

This edition of the Genetic TOE depicts the current landscape and the new life sciences trends across technologies empowering diagnostics.The technology synergy observed to address current concerns in cancer diagnostics and the development of monoclonal antibodies to target Parkinson's disease are illustrated. The corresponding patent scenario is also depicted along with industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covere

Table of Contents

Technologies Empowering Diagnostics - Genetic TOETechnology ProfilesNovel 3D Bioprinting PlatformTargeted Antibodies for Parkinson's DiseaseSkin Cancer Detection Using Raman Spectroscopy Solutions Genetic Tests Are More Comprehensive and Suitable for Medical Assessment in Developing Treatments AppendixPatent ScenarioPatent Scenario (continued)Industry Interactions




Related Research

Release Date : 28-Sep-18

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.